Symbols / MTNB
MTNB Chart
About
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.10M |
| Enterprise Value | 902.87K | Income | -17.48M | Sales | — |
| Book/sh | 1.09 | Cash/sh | 0.85 | Dividend Yield | — |
| Payout | 0.00% | Employees | 3 | IPO | — |
| P/E | — | Forward P/E | -0.21 | PEG | — |
| P/S | — | P/B | 0.58 | P/C | — |
| EV/EBITDA | -0.10 | EV/Sales | — | Quick Ratio | 3.63 |
| Current Ratio | 3.78 | Debt/Eq | 36.13 | LT Debt/Eq | — |
| EPS (ttm) | -3.42 | EPS next Y | -3.00 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-08-13 16:00 | ROA | -38.81% |
| ROE | -151.68% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 6.41M |
| Shs Float | 5.23M | Short Float | 0.01% | Short Ratio | 0.01 |
| Short Interest | — | 52W High | 3.09 | 52W Low | 0.47 |
| Beta | 1.33 | Avg Volume | 35.87K | Volume | 4.02K |
| Target Price | — | Recom | None | Prev Close | $0.62 |
| Price | $0.64 | Change | 2.40% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.64
Latest analyst target
3. DCF / Fair value
$-11.88
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.64
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-10-31 | down | Maxim Group | Buy → Hold | — |
| 2023-01-31 | reit | HC Wainwright & Co. | — → Buy | $3 |
| 2020-08-13 | main | Aegis Capital | — → Buy | $4 |
| 2020-01-27 | init | Piper Sandler | — → Overweight | $3 |
| 2020-01-24 | init | SunTrust Robinson Humphrey | — → Buy | $3 |
| 2019-06-26 | init | HC Wainwright & Co. | — → Buy | $4 |
| 2019-05-17 | init | BTIG | — → Buy | $5 |
| 2019-02-11 | init | Roth Capital | — → Buy | — |
| 2018-11-13 | main | Maxim Group | Buy → Buy | $5 |
| 2018-08-13 | main | Maxim Group | Buy → Buy | $2 |
| 2018-07-10 | main | Maxim Group | Buy → Buy | $3 |
- Matinas BioPharma Holdings, Inc. (MTNB) Restructures Amid Challenges, Focuses on Oral Antifungal MAT2203 - Yahoo Finance ue, 23 Sep 2025 07
- Matinas BioPharma CEO Named Interim Chief Financial Officer - The Globe and Mail Sat, 24 Jan 2026 08
- Why Matinas BioPharma Tumbled 13.4% Today - The Motley Fool Mon, 16 Dec 2019 08
- Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair - Stock Titan Fri, 07 Feb 2025 08
- MTNB Stock Price and Chart — AMEX:MTNB - TradingView Sat, 29 Jul 2017 04
- Matinas BioPharma Announces the Termination of MAT2203 - GlobeNewswire hu, 31 Oct 2024 07
- Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch - InvestorPlace hu, 16 May 2024 07
- 12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga Fri, 23 Jan 2026 08
- 4 Cheap Penny Stocks To Buy On Robinhood For Under $1 Right Now - Yahoo Finance Mon, 13 Sep 2021 07
- Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation - Stock Titan Mon, 25 Mar 2024 07
- Should You Be Concerned About Matinas BioPharma Holdings, Inc.'s (NYSEMKT:MTNB) Historical Volatility? - Yahoo Finance Mon, 28 Oct 2019 07
- Here's Why Matinas BioPharma Holdings Inc. Is Losing Ground Today - The Motley Fool Mon, 26 Jun 2017 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -14.62K | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -14.76M | -23.31M | -27.18M | -25.28M |
| TotalUnusualItems | -4.43M | 484.00K | 3.49M | 1.33M |
| TotalUnusualItemsExcludingGoodwill | -4.43M | 484.00K | 3.49M | 1.33M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -24.25M | -22.94M | -21.00M | -23.28M |
| ReconciledDepreciation | 972.00K | 941.00K | 898.00K | 781.00K |
| EBITDA | -19.19M | -22.82M | -23.69M | -23.95M |
| EBIT | -20.16M | -23.77M | -24.59M | -24.73M |
| NormalizedIncome | -19.83M | -23.43M | -24.49M | -24.61M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -24.25M | -22.94M | -21.00M | -23.28M |
| TotalExpenses | 20.16M | 24.86M | 27.78M | 24.77M |
| TotalOperatingIncomeAsReported | -24.59M | -23.77M | -24.59M | -24.73M |
| DilutedAverageShares | 4.87M | 4.35M | 4.34M | 4.20M |
| BasicAverageShares | 4.87M | 4.35M | 4.34M | 4.20M |
| DilutedEPS | -4.98 | -5.28 | -5.00 | -5.50 |
| BasicEPS | -4.98 | -5.28 | -5.00 | -5.50 |
| DilutedNIAvailtoComStockholders | -24.25M | -22.94M | -21.00M | -23.68M |
| NetIncomeCommonStockholders | -24.25M | -22.94M | -21.00M | -23.68M |
| PreferredStockDividends | 396.00K | |||
| NetIncome | -24.25M | -22.94M | -21.00M | -23.28M |
| NetIncomeIncludingNoncontrollingInterests | -24.25M | -22.94M | -21.00M | -23.28M |
| NetIncomeContinuousOperations | -24.25M | -22.94M | -21.00M | -23.28M |
| TaxProvision | -80.00K | 0.00 | ||
| PretaxIncome | -24.33M | -22.94M | -21.00M | -23.28M |
| OtherIncomeExpense | -4.17M | 824.00K | 3.59M | 1.45M |
| OtherNonOperatingIncomeExpenses | 262.00K | 340.00K | 102.00K | 124.00K |
| SpecialIncomeCharges | -4.43M | 484.00K | 3.49M | 1.33M |
| GainOnSaleOfBusiness | 0.00 | 484.00K | 3.49M | 1.33M |
| ImpairmentOfCapitalAssets | 4.43M | 0.00 | ||
| OperatingIncome | -20.16M | -23.77M | -24.59M | -24.73M |
| OperatingExpense | 20.16M | 24.86M | 27.78M | 24.77M |
| ResearchAndDevelopment | 11.43M | 14.49M | 16.68M | 14.58M |
| SellingGeneralAndAdministration | 8.73M | 10.37M | 11.10M | 10.19M |
| GeneralAndAdministrativeExpense | 8.73M | 10.37M | 11.10M | 10.19M |
| OtherGandA | 8.73M | 10.37M | 11.10M | 10.19M |
| TotalRevenue | 0.00 | 1.10M | 3.19M | 33.00K |
| OperatingRevenue | 0.00 | 1.10M | 3.19M | 33.00K |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 5.09M | 4.35M | 4.35M | 4.33M |
| ShareIssued | 5.09M | 4.35M | 4.35M | 4.33M |
| TotalDebt | 2.89M | 3.56M | 4.12M | 4.70M |
| TangibleBookValue | 5.33M | 14.89M | 32.28M | 48.14M |
| InvestedCapital | 7.59M | 19.25M | 36.64M | 52.49M |
| WorkingCapital | 5.36M | 12.92M | 30.25M | 46.65M |
| NetTangibleAssets | 5.33M | 14.89M | 32.28M | 48.14M |
| CapitalLeaseObligations | 2.89M | 3.56M | 4.12M | 4.70M |
| CommonStockEquity | 7.59M | 19.25M | 36.64M | 52.49M |
| TotalCapitalization | 7.59M | 19.25M | 36.64M | 52.49M |
| TotalEquityGrossMinorityInterest | 7.59M | 19.25M | 36.64M | 52.49M |
| StockholdersEquity | 7.59M | 19.25M | 36.64M | 52.49M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | -221.00K | -824.00K | -145.00K |
| OtherEquityAdjustments | -221.00K | -824.00K | -145.00K | |
| RetainedEarnings | -199.82M | -175.57M | -152.63M | -131.63M |
| AdditionalPaidInCapital | 207.41M | 195.04M | 190.07M | 184.25M |
| CapitalStock | 1.00K | 0.00 | 22.00K | 22.00K |
| CommonStock | 1.00K | 0.00 | 22.00K | 22.00K |
| PreferredStock | 0.00 | |||
| TotalLiabilitiesNetMinorityInterest | 5.05M | 5.86M | 8.18M | 8.83M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.38M | 3.24M | 3.90M | 4.48M |
| NonCurrentDeferredLiabilities | 257.00K | 341.00K | 341.00K | 341.00K |
| NonCurrentDeferredTaxesLiabilities | 257.00K | 341.00K | 341.00K | 341.00K |
| LongTermDebtAndCapitalLeaseObligation | 2.13M | 2.90M | 3.56M | 4.14M |
| LongTermCapitalLeaseObligation | 2.13M | 2.90M | 3.56M | 4.14M |
| CurrentLiabilities | 2.67M | 2.62M | 4.29M | 4.35M |
| OtherCurrentLiabilities | 4.00K | 271.00K | 585.00K | 576.00K |
| CurrentDeferredLiabilities | 0.00 | 809.00K | 932.00K | |
| CurrentDeferredRevenue | 0.00 | 721.00K | 33.00K | |
| CurrentDebtAndCapitalLeaseObligation | 766.00K | 661.00K | 569.00K | 560.00K |
| CurrentCapitalLeaseObligation | 766.00K | 661.00K | 569.00K | 560.00K |
| PayablesAndAccruedExpenses | 1.90M | 1.96M | 2.91M | 2.86M |
| CurrentAccruedExpenses | 1.80M | 1.45M | 2.29M | 1.92M |
| Payables | 95.00K | 514.00K | 618.00K | 937.00K |
| AccountsPayable | 95.00K | 514.00K | 618.00K | 937.00K |
| TotalAssets | 12.64M | 25.10M | 44.82M | 61.33M |
| TotalNonCurrentAssets | 4.62M | 9.56M | 10.29M | 10.33M |
| OtherNonCurrentAssets | 200.00K | 200.00K | 200.00K | 200.00K |
| GoodwillAndOtherIntangibleAssets | 2.26M | 4.35M | 4.35M | 4.35M |
| OtherIntangibleAssets | 2.26M | 3.02M | 3.02M | 3.02M |
| Goodwill | 0.00 | 1.34M | 1.34M | 1.34M |
| NetPPE | 2.16M | 5.01M | 5.73M | 5.78M |
| AccumulatedDepreciation | -2.06M | -1.70M | -1.37M | -1.04M |
| GrossPPE | 4.22M | 6.70M | 7.10M | 6.82M |
| Leases | 993.00K | 1.16M | 1.16M | 935.00K |
| OtherProperties | 3.22M | 5.55M | 5.95M | 5.88M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 8.03M | 15.54M | 34.53M | 50.99M |
| OtherCurrentAssets | 691.00K | 1.74M | 5.72M | 1.32M |
| RestrictedCash | 50.00K | 50.00K | 50.00K | 50.00K |
| PrepaidAssets | 1.32M | |||
| CashCashEquivalentsAndShortTermInvestments | 7.28M | 13.76M | 28.76M | 49.62M |
| OtherShortTermInvestments | 0.00 | 8.97M | 21.93M | 28.59M |
| CashAndCashEquivalents | 7.28M | 4.79M | 6.83M | 21.03M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -15.88M | -15.50M | -20.05M | -15.48M |
| RepaymentOfDebt | -5.00K | -7.00K | -20.00K | -30.00K |
| IssuanceOfCapitalStock | 9.18M | 0.00 | 0.00 | 5.58M |
| CapitalExpenditure | -218.00K | -892.00K | -260.00K | |
| EndCashPosition | 7.53M | 5.04M | 7.08M | 21.28M |
| BeginningCashPosition | 5.04M | 7.08M | 21.28M | 12.77M |
| ChangesInCash | 2.50M | -2.04M | -14.20M | 8.51M |
| FinancingCashFlow | 9.17M | -7.00K | 79.00K | 6.96M |
| CashFlowFromContinuingFinancingActivities | 9.17M | -7.00K | 79.00K | 6.96M |
| ProceedsFromStockOptionExercised | 0.00 | 99.00K | 1.42M | |
| NetCommonStockIssuance | 9.18M | 0.00 | 0.00 | 5.58M |
| CommonStockIssuance | 9.18M | 0.00 | 0.00 | 5.58M |
| NetIssuancePaymentsOfDebt | -5.00K | -7.00K | -20.00K | -30.00K |
| NetLongTermDebtIssuance | -5.00K | -7.00K | -20.00K | -30.00K |
| LongTermDebtPayments | -5.00K | -7.00K | -20.00K | -30.00K |
| InvestingCashFlow | 9.21M | 13.24M | 4.88M | 16.77M |
| CashFlowFromContinuingInvestingActivities | 9.21M | 13.24M | 4.88M | 16.77M |
| NetInvestmentPurchaseAndSale | 9.21M | 13.46M | 5.77M | 17.03M |
| SaleOfInvestment | 17.64M | 13.46M | 15.25M | 40.23M |
| PurchaseOfInvestment | -8.44M | 0.00 | -9.48M | -23.20M |
| NetPPEPurchaseAndSale | 0.00 | -218.00K | -892.00K | -260.00K |
| PurchaseOfPPE | 0.00 | -218.00K | -892.00K | -260.00K |
| OperatingCashFlow | -15.88M | -15.28M | -19.16M | -15.22M |
| CashFlowFromContinuingOperatingActivities | -15.88M | -15.28M | -19.16M | -15.22M |
| ChangeInWorkingCapital | -131.00K | 1.67M | -4.79M | 1.53M |
| ChangeInOtherCurrentLiabilities | -655.00K | -562.00K | -520.00K | -460.00K |
| ChangeInPayablesAndAccruedExpense | -63.00K | -1.75M | -72.00K | 645.00K |
| ChangeInAccruedExpense | 356.00K | -1.65M | 249.00K | 57.00K |
| ChangeInPayable | -419.00K | -103.00K | -321.00K | 588.00K |
| ChangeInAccountPayable | -419.00K | -103.00K | -321.00K | 588.00K |
| ChangeInPrepaidAssets | 587.00K | 3.98M | -4.20M | 1.35M |
| OtherNonCashItems | -17.00K | 107.00K | 502.00K | 1.45M |
| StockBasedCompensation | 3.19M | 4.95M | 5.23M | 4.29M |
| AssetImpairmentCharge | 4.43M | 0.00 | ||
| DeferredTax | -84.00K | 0.00 | ||
| DeferredIncomeTax | -84.00K | 0.00 | ||
| DepreciationAmortizationDepletion | 972.00K | 941.00K | 898.00K | 781.00K |
| DepreciationAndAmortization | 972.00K | 941.00K | 898.00K | 781.00K |
| Depreciation | 972.00K | 941.00K | 898.00K | 781.00K |
| OperatingGainsLosses | 1.00K | 2.00K | 2.00K | |
| GainLossOnSaleOfPPE | 0.00 | 1.00K | 2.00K | 2.00K |
| NetIncomeFromContinuingOperations | -24.25M | -22.94M | -21.00M | -23.28M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for MTNB
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|